Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

1484 A Case of Medication-Related Central Apnea During Wakefulness
Eggleston, Reid, Dupuy-McCauley, Kara , Eggleston, Reid

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A635-A636

10.1093/sleep/zsaf090.1484 Get It

Abstract Introduction Tizanidine is an alpha-2 receptor adrenergic agonist employed for treatment of musculoskeletal pain and muscle spasticity. Drowsiness, xerostomia, and, less frequently, sleep disturbance are notable side effects. Central sleep apnea (CSA) occurs in patients taking other alpha-2 receptor agonists such as clonidine but the frequency of CSA among users of tizanidine is less well-known. Rarer still is the presence of central apneic episodes during wakefulness in patients without heart failure who have an intact brainstem and are not taking opioids or benzodiazepines. We report a case of a patient with central apneic episodes during wakefulness in the setting of tizanidine use. Report of case A 60-year-old white male was referred to our sleep center for sleep apnea. He was previously diagnosed with severe obstructive sleep apnea (apnea-hypopnea index of 104 events per hour) but was not adherent to continuous positive airway pressure (CPAP) due to a previous head injury which made use of CPAP straps intolerably painful. Thus, he had undergone a modified uvulopalatopharyngoplasty 3 months prior to evaluation. Despite UPPP he continued to have excessive daytime sleepiness. A repeat polysomnogram revealed frequent central apneic episodes during periods of wakefulness that did not persist after sleep onset. The patient had taken his nightly tizanidine 8 mg prior to testing. Echocardiogram prior to testing showed mild diastolic dysfunction and brain magnetic resonance imaging was unremarkable. A polysomnogram was repeated 1 month later, this time with tizanidine held for 1 week prior to testing. Wake-onset central apneic episodes had resolved without any other changes in medication or health status. Conclusion Certain medications such as opioids, benzodiazepines, and baclofen are known to induce CSA. However, to the best of our knowledge this is the first case of a commonly prescribed alpha-2 agonist implicated in the development of wake-onset central apneic episodes. More study is needed to elucidate the impact of tizanidine on ventilatory function in the wake and sleep states and whether similar effects may occur among other centrally acting medications. Support (if any)
1420 Buprenorphine-Naloxone for the Treatment of Medically Refractory Restless Legs Syndrome: A Case Series
Sherfinski, Emma, Chaudhary, Hira, Tashman, Yasemin

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A610-A610

10.1093/sleep/zsaf090.1420 Get It

Abstract Introduction Restless Legs Syndrome (RLS) affects up to 3% of the adult population in the United States, with approximately one-third of these individuals experiencing medically refractory disease. Historically, treatments for RLS have included iron replacement, dopamine agonists, and alpha-2-delta ligands. However, dopamine agonists are often associated with augmentation, a phenomenon in which RLS symptoms worsen. This includes increased severity, earlier onset, spread of symptoms to other parts of the body, and the need for higher doses of medications. Over the past decade, the use of opioid therapy for refractory RLS has become more widely accepted. Buprenorphine-naloxone, a combination medication, includes buprenorphine, a partial agonist at the mu-opioid receptor, which is less likely to cause respiratory depression, overdose, or euphoria compared to full agonists. Naloxone, an opioid antagonist, is included to deter misuse. Here, we share the treatment responses of three patients with refractory RLS who were treated with buprenorphine-naloxone. Report of case Pre- and post-treatment IRLS were compared in three Sleep Medicine patients (two females, aged 70, and one male, aged 72) on therapeutic doses of buprenorphine-naloxone. Patient charts were reviewed for medication side effects. Previous treatments included dopamine agonists, alpha-2-delta ligands, iron supplementation, benzodiazepines, methadone, and melatonin. Pre-treatment IRLS scores were 13, 13, and 24, classified as moderate to severe. The formulations used included buprenorphine-naloxone 2-0.5 mg sublingual tablets and buprenorphine-naloxone 2-0.5 mg 1/8 films. Therapeutic daily doses of buprenorphine-naloxone ranged from 7.5 to 60 morphine milligram equivalents (MME) per day. Post-treatment IRLS scores were 0, 2, and 3, representing an average reduction of over 15 points on the IRLS. Average time between pre- and post-treatment IRLS was 29 months. Side effects were reported by one patient, including fatigue, depressive symptoms, and reflux, but none of the patients experienced side effects that limited the use of the medication. Conclusion In this case series, we demonstrate the positive impact of buprenorphine-naloxone in managing refractory RLS, as evidenced by substantial reductions in IRLS scores from moderate to severe levels. We hope to encourage clinicians to consider buprenorphine-naloxone as an effective and well-tolerated treatment option for patients with refractory RLS. Support (if any)
1280 Characteristics of Sleep Disturbance in Patients with Moyamoya
Ahmad, Mudassar, Klaas, James P. , Lanzino, Giuseppe, StLouis, Erik, Rinaldo, Lorenzo , Ahmad, Mudassar, Lanzino, Giuseppe , McCarter, Stuart J. , Carvalho, Diego

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A551-A551

10.1093/sleep/zsaf090.1280 Get It

Abstract Introduction Moyamoya is characterized by idiopathic, progressive, large intracranial arterial steno-occlusion, affecting the anterior circulation of the brain. Common presentations include strokes, seizures, and headaches, which have been associated with poor sleep quality and sleep disorders in the general population. However, to our knowledge, sleep quality has not been previously investigated in Moyamoya disease. The aim of this study was to characterize self-reported sleep quality, sleepiness, sleep disorder diagnoses in patients with Moyamoya syndrome, and to explore possible association between sleep disturbance and quality of life in these patients. Methods We analyzed consecutive patients with Moyamoya evaluated at our institution who completed the Pittsburgh Sleep Quality Index (PSQI) and the Epworth Sleepiness Scale (ESS). We also abstracted the Patient-Reported Outcomes Measurement Information System (PROMIS) to measure person-centered physical, mental and social wellbeing. Results We studied 23 patients with mean age 41.8 ± 12.1 years old having disease duration of 3 ± 4.4 years. 15 (65.2%) had ischemic strokes. Mean total PSQI score was 6.9 ± 2.9, and 17 (73.9%) had poor sleep quality (PSQI>5). Mean sleep efficiency was reduced at 80 ± 17%. Although Median ESS was 6 (IQR 3.25 – 8), most patients (91.3%) reported at least mild daytime dysfunction (Component 7≥1). Mean PSQI component scores (0 – 3 severity, 3 is worse) were 1.29 ± 0.62 (subjective quality), 1.1 ± 0.73 (sleep latency), 1.04 ± 0.83 (sleep duration), 0.87 ± 1.01 (sleep efficiency), 1.22 ± 0.52 (sleep disturbances), 0.3 ± 0.88 (sleep medication), and 1.1 ± 0.52 (daytime dysfunction). The total PSQI score was positively correlated with PROMIS score (r=0.47, p=0.044). Only one patient was diagnosed with obstructive sleep apnea and three with chronic insomnia. Conclusion Poor sleep quality appears to be a frequent problem in patients with Moyamoya disease. Sleep disturbance severity was similar to previous findings in clinical stroke populations. The apparent mismatch between subjective sleep disturbance and sleep disorder diagnoses suggest that sleep disorders are likely underdiagnosed in Moyamoya patients. The relationship between PSQI and PROMIS scores suggests that sleep disturbance may significantly affect quality of life in these patients. Support (if any)
1266 Sleep Trajectories Across Three Cognitive-Aging Pathways in Community Dwelling Older Adults
Tapia, Amanda, Oryshkewych, Nina , Butters, Meryl A. , Buysse, Daniel J. , Yu, Lan , Soehner, Adriane M. , Wallace, Meredith L. , Zaheed, Afsara B. , Wheeler, Bradley J. , Leng, Yue , Barnes, Lisa L. , Lim, Andrew S. P.

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A545-A545

10.1093/sleep/zsaf090.1266 Get It

Abstract Introduction Comparing sleep and rest-activity rhythms (RARs) across the spectrum of cognitive aging can reveal novel risk factors and potential mechanisms underlying dementia disorders. However, our current understanding is restricted by differences in sleep measurement, limited longitudinal data, and heterogeneous cognitive aging processes. We aimed to determine (1) which sleep/RAR features exhibit meaningful changes within three distinct cognitive pathways; and (2) which sleep/RAR features differ between cognitive aging pathways prior to and after the onset of mild cognitive impairment (MCI) and/or dementia. Methods Longitudinal self-reported sleep and actigraphy data were obtained from 1,449 participants in the Rush Memory and Aging Project (mean age= 81.2±7.1 years, 75.2% female, 5.2% Black, 94.8% White). We applied flexible cubic spline models to quantify differences in the levels and trajectories of sleep amount (self-reported duration; actigraphy rest interval length and alpha), regularity (actigraphy interdaily stability, intradaily variability, and midpoint standard deviation), and timing (self-reported midpoint; actigraphy midpoint and acrophase) within and between three cognitive aging pathways over 12 years: Normal Cognitive Aging (‘Normal’), Progression to MCI (‘Stable MCI’), and Progression to Dementia (‘Dementia’). Models were adjusted for key sociodemographic and health variables. Results Sleep amount was lowest in the Dementia pathway prior to MCI or dementia, but increased with age, most rapidly following dementia. The greatest effect was observed in self-reported duration (standardized mean change, d[95%CI]=0.912 [0.47, 1.36]. Regularity declined across all pathways, most rapidly after cognitive diagnoses, with the largest increases in intradaily variability occurring among the Stable MCI (d=0.97 [0.70, 1.23]) and Dementia paths (d=1.11 [0.84, 1.38). Shifts toward earlier sleep timing were observed in actigraphy measures across all three pathways (-0.54≤d≤-0.31). Conclusion Shorter sleep amount in cognitively healthy older adults may be a risk factor or prodromal indicator of dementia, while longer sleep amounts and decreasing regularity following dementia may reflect neurodegeneration. Advances in sleep timing may be less useful as a clinical indicator of future cognitive impairment or decline. Differences between self-reported and actigraphy-measured sleep/RAR outcomes may reflect distinct underlying mechanisms, warranting further research. Support (if any) NIH: T32HL082610, RF1AG056331, R01AG052488, R01AG071638, RF1AG070436, R01AG17917
0798 Assessment of Oral Appliance Therapy Efficacy in Stroke Patients with Obstructive Sleep Apnea
Herzog, Tyler L. , Giri, Subha , Herold, Daniel L. , Lipford, Melissa C.

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A345-A346

10.1093/sleep/zsaf090.0798 Get It

Abstract Introduction Sleep apnea impacts 50-70% of patients following stroke. Treatment of obstructive sleep apnea (OSA) in patients with stroke using continuous positive airway pressure (CPAP) has been recommended in recent American Heart Association/American Stroke Association guidelines. However, stroke patients poorly tolerate CPAP and often remain untreated. There is a paucity of data regarding alternative treatments such as oral appliance therapy (OAT) in stroke patients. We hypothesized that oral appliance therapy would be an efficacious option in the treatment of OSA in stroke patients, defined as a ≥50% reduction in apnea-hypopnea index (AHI) or oxygen desaturation index (ODI) or reduction in total AHI or ODI to < 10/h. Methods We performed a retrospective review of patients with OSA treated with OAT at our institution and had a history of stroke prior to receiving the oral appliance. Chart abstraction included demographic data, stroke type, sleep apnea diagnostic data, and efficacy data. Efficacy data included repeat sleep studies, overnight oximetry, patient reported outcomes, and subjective benefit, as available. Results 23 patients (52% female, mean age 63) were identified with a history of stroke prior to use of OAT for OSA. Baseline parameters (mean, SD) included BMI (30.8, 4.2), AHI (15.0, 10.6), and Epworth Sleepiness Scale (ESS) (9.3, 5.4). Post-treatment parameters included (mean, SD) BMI (30.1, 4.2), AHI (12.4, 12.0), and ESS (6.5, 4.0). 12 patients had both baseline and follow-up sleep studies performed which met criteria for AHI efficacy of OAT in 7 of 12 (58%). Wilcoxon signed rank exact test demonstrated improvement in median AHI of 9.3 (0.40-17.6, p< 0.05) among these 12 patients. 2 of 3 (67%) patients with overnight oximetry follow-up met criteria for ODI efficacy of OAT. Of 8 patients with only subjective follow-up, 6 (75%) reported subjective improvement and 2 (25%) did not tolerate the device. Conclusion This study demonstrated that oral appliance therapy is efficacious in reducing the AHI by at least 50% or to a value below 10 in a majority of patients. Oral appliance therapy may be a viable alternative to CPAP in selected OSA patients with a history of stroke. Support (if any) No support
0843 ENCORE: Topline Results of a Phase 3 Open-Label Extension and Randomized-Withdrawal Trial of AXS-12 in Narcolepsy
Thorpy, Michael J., Krahn, Lois E., Corser, Bruce, Shapiro, Colin M. , Chhabra, Angad, Tabuteau, Herriot, Bogan, Richard , Leary, Eileen

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A365-A366

10.1093/sleep/zsaf090.0843 Get It

Abstract Introduction AXS-12 (reboxetine) is a highly selective norepinephrine reuptake inhibitor and cortical dopamine modulator under development for narcolepsy. In the Phase 3 SYMPHONY trial, AXS-12 significantly reduced weekly cataplexy attacks from baseline to Week 5 versus placebo in patients with narcolepsy. Here we report the Phase 3 ENCORE trial, assessing long-term efficacy and safety of AXS-12 in participants who completed SYMPHONY. Methods ENCORE included a 24-week open-label extension (OLE) period, followed by a 3-week double-blind randomized-withdrawal (DBRW) period. During the OLE, participants received AXS-12 (5 mg once-daily for 1 week, twice-daily for 23 weeks). Following this, remaining participants were randomized 1:1 to continue twice-daily AXS-12 or switch to once-daily AXS-12 plus placebo for 1 week, then placebo twice-daily for 2 weeks. The primary endpoint was change in frequency of cataplexy attacks from randomization to DBRW Week 3. OLE efficacy outcomes included change in weekly frequency of cataplexy attacks, cataplexy response (≥50% reduction), and change in cataplexy-free days. Additional analyses are ongoing. Results ENCORE enrolled 68 participants; 42 completed the OLE and entered the DBRW (AXS-12, n=22; placebo, n=20). In SYMPHONY, baseline mean weekly frequency of cataplexy attacks was 31.5. At DBRW randomization, mean weekly frequency of cataplexy attacks was 4.2 (AXS-12) and 6.9 (placebo). Participants randomized to placebo experienced a mean increase of 10.29 weekly cataplexy attacks versus 1.32 for AXS-12, at end of DBRW (p=0.017). In the OLE, weekly frequency of cataplexy attacks decreased by 22.3 (71%) and 24.1 (77%) at 1 and 6 months, respectively. Cataplexy response was achieved by 72% and 82% at 1 and 6 months, respectively. Cataplexy-free days increased from 14.3% to 61% and 70% at 1 and 6 months, respectively. Common adverse events (AEs; ≥5%) during the OLE were nausea and tachycardia (both 5.9%); no new safety signals were detected. Discontinuations due to AEs occurred in 17.6% of participants in the OLE. Conclusion AXS-12 significantly reduced the frequency of cataplexy attacks during the DBRW. AXS-12 was well-tolerated and demonstrated maintenance of efficacy with long-term open-label use. These results align with SYMPHONY, supporting the positive therapeutic impact of AXS-12 for narcolepsy. Support (if any) Axsome Therapeutics, Inc.
1003 A Pilot Study of the SleepImage Home Sleep Apnea Test Compared to Polysomnography in Children 2 to 6 Years of Age
Murray, Ann , Matarese, Christine, Lloyd, Robin M. , Sorensen, Channing, Reckward, Dennis, Tullis, Robyn, Bellinger, Mark F., Brown, Ginny, Herold, Daniel L. , Baughn, Julie , Murray, Ann, Morgenthaler, Timothy I. , LeMahieu, Allison , Bellinger, Mark

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A434-A434

10.1093/sleep/zsaf090.1003 Get It

Abstract Introduction The SleepImage is an HSAT device (sHSAT) that uses photoplethysmography and oxygen saturation data to generate an apnea hypopnea index (AHI). This sHSAT has been FDA cleared as a software-as-a-medical-device for use in children 2 years and older for diagnosing obstructive sleep apnea (OSA). To our knowledge this sHSAT has not been tested on children concurrent with the gold standard polysomnography (PSG). Methods This study evaluated 50 children 2-6 years of age with tonsillar hypertrophy and OSA symptoms with sHSAT during simultaneous in-lab PSG. Aims were to determine the technical feasibility of using sHSAT in this population and to compare sHSAT results to PSG. The primary endpoint was AHI by sHSAT compared to AHI by PSG and presence of OSA. Sensitivity analysis was performed for presence or absence of OSA diagnosis based on sHSAT versus PSG. Bland-Altman and concordance correlation calculations were used for comparisons. Results 50 patients, median age 4 (IQR 3-5), met criteria; 39 completed PSG and HSAT. The sensitivity with sHSAT for OSA prevalence based on proprietary categorization was 94.1%, specificity 22.7%, LR+ 1.22, and LR- 0.26, with PSG OSA prevalence of 43.6%. There was a 9% sHSAT total failure rate, and the device frequently fell off, resulting in TST difference of -226.9 ±182.8 min between sHSAT and PSG. PSG was trimmed to include only segments where HSAT was confirmed to be on before comparisons. Concordance correlation coefficient between sAHI and AHI-PSG was 0.52. The Bland-Altman analysis comparing sAHI and PSG AHI revealed a mean difference of 0.73 (95% confidence limits: -3.47 to 4.93). Considering only obstructive events, the Bland-Altman the sAHI vs the AHI-PSG shows a mean difference of 1.52 (95%CI -5.40 to 8.44). Conclusion This pilot study demonstrated challenges with feasibility in using the sHSAT in this age group given likelihood of technical difficulties leading to absent or truncated data. When compared with PSG, sHSAT demonstrated a high false-positive rate for diagnosis of OSA, particularly concerning if guiding surgical management. This topic is of considerable importance to the practice of pediatric sleep medicine; further investigation of technological advances in this area is imperative. Support (if any)
0723 Hypopnea Classification Impact on Transvenous Phrenic Nerve Stimulation Therapy Patient Selection and Efficacy
Dupuy-McCauley, Kara , Javaheri, Shahrokh, Germany, Robin , Schwartz, Alan R. , McKane, Scott , Morgenthaler, Timothy I.

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A314-A315

10.1093/sleep/zsaf090.0723 Get It

Abstract Introduction Despite AASM scoring guidelines encouraging classifying hypopneas as central or obstructive, classification is underutilized in practice. However, without that effort patients may receive an incorrect primary diagnosis and suboptimal treatment. The remedē® System Pivotal Trial studied transvenous phrenic nerve stimulation (TPNS) to treat adult patients with moderate to severe central sleep apnea (CSA). Entry criteria required apnea hypopnea index (AHI)≥20 with the central apnea index (CAI) greater than the obstructive apnea index and obstructive apneas< 20% of AHI but did not consider hypopnea differentiation. This analysis re-examined sleep studies from the trial to assess how hypopnea classification might lead to better patient selection for this therapy. Methods Hypopneas were classified as central versus obstructive by a sleep core laboratory following a modified version of AASM recommended criteria. The AHI composition was assessed at baseline and after 6 months of therapy. Results At baseline, 91% (138/151) of patients had ≥50% of events classified as central when accounting for hypopnea classification. If all hypopneas were assumed to be obstructive, only 63% (95/151) would have had ≥50% central events. Additionally, 95% (144/151) of patients had central AHI ≥15/hour, compared to 73% (110/151) with a central apnea index (CAI) ≥15/hour. The likelihood of achieving a ≥50% AHI reduction increased with the percentage of baseline events that were central: responder rates were 37.5% for patients with < 50% central events at baseline, incrementally increasing to 76.5% for those with ≥90% central events. At 6 months, the residual AHI predominantly consisted of obstructive events. Central events decreased by 89% with treatment, from a baseline median of 32/hour [1st and 3rd quartiles: 22, 50]. Obstructive apneas rose by 2/hour and obstructive hypopneas increased by 2/hour from a baseline median of 5 obstructive events/hour [2, 12]. Conclusion Distinguishing central from obstructive hypopneas is required to accurately determine if a patient has central sleep apnea/Cheyne Stokes respiration, and is crucial for epidemiologic studies, appropriate therapy selection, and managing patient expectations about treatment outcomes. This analysis suggests that accurate hypopnea classification may prevent disqualification of patients who could benefit from TPNS therapy, which effectively treats central sleep apnea syndrome. Support (if any) ZOLL Respicardia, Inc.
0831 Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Results from the DUET Study
Schneider, Logan , Ruoff, Chad , Nichols, Deborah A. , Steininger, Teresa L. , Fuller, Douglas S. , Akerman, Sarah , Alexander, Jessica, Whalen, Marisa, Cairns, Alyssa , Ruoff, Chad M , Plante, David T. , Kirby, M

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A360-A360

10.1093/sleep/zsaf090.0831 Get It

Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) assessing the effectiveness of low-sodium oxybate (LXB; Xywav®) treatment on daytime and nighttime symptoms in participants with narcolepsy (type 1 [NT1] or 2 [NT2]) or idiopathic hypersomnia. Data presented are from the narcolepsy cohort. Methods DUET included a screening period (with 2-week washout for current oxybate users), 8-day baseline (BL) period, 2- to 8-week LXB titration period, 2-week stable-dose period, 8-day end-of treatment (EOT) period, and 2-week safety follow-up. The primary endpoint was change in Epworth Sleepiness Scale (ESS) score from BL to EOT. Key secondary endpoints for the narcolepsy cohort included change in polysomnography parameters: total shifts from deeper to lighter sleep stages, stage N3 sleep duration (minutes), and number of awakenings. Additional endpoints included Patient Global Impression of Change (PGIc)–overall narcolepsy disease. Primary and key secondary endpoints were controlled for multiplicity with sequential testing; other P-values are considered nominal. Results Fifty-five narcolepsy participants enrolled and were dosed with LXB (NT1, n=26; NT2, n=29); 13 transferred to another cohort and 34 were completers (NT1, n=16; NT2, n=18). Enrolled participants were mostly female (72.7%) and White (80.0%); mean (SD) age was 33.4 (12.9) years (NT1=34.6 [12.6]; NT2=32.4 [13.2]). For completers, least-squares mean (LSM) (SE) changes in ESS score were −7.7 (0.9), P<.0001, overall; NT1=−6.5 (1.4), P<.0001; NT2=−8.8 (1.3), P<.0001. Compared with BL, sleep architecture at EOT showed fewer deeper to lighter sleep stage shifts (LSM [SE]: −13.1 [2.9], P<.0001, overall; NT1=−13.9 [4.3], P=0.0029; NT2=−12.3 [4.1], P=0.0050); increased stage N3 sleep (minutes) (45.0 [8.8], P<.0001, overall; NT1=49.8 [13.0], P=0.0006; NT2=40.8 [12.3], P=0.0023); and fewer awakenings (−3.2 [0.9], P=0.0015, overall; NT1=−4.1 [1.4], P=0.0056; NT2=−2.3 [1.3], P=0.0771). Most participants (93.3%, n=30; NT1, 86.7%, n=15; NT2, 100%, n=15) reported improvement (very much, much, minimally) in overall narcolepsy disease on PGIc. Treatment-emergent adverse events were consistent with the known safety profile of LXB. Conclusion Participants with NT1 and NT2 taking open-label LXB showed improvements in daytime sleepiness (decreased ESS scores) and reduced symptom burden (improved PGIc), which paralleled improvements in sleep architecture and disruption. Support (if any) Jazz Pharmaceuticals
0828 Impact of AXS-12 on Symptom Severity and Functional Impairment in Narcolepsy: Results from the Phase 3 SYMPHONY Trial
Thorpy, Michael J., Krahn, Lois E., Corser, Bruce, Shapiro, Colin M. , Chhabra, Angad, Tabuteau, Herriot, Bogan, Richard , Chen, Dan , Leary, Eileen

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A359-A359

10.1093/sleep/zsaf090.0828 Get It

Abstract Introduction Narcolepsy is a chronic neurologic condition associated with severe symptom burden, impaired functioning and reduced quality of life. Patients commonly report comorbid mood disorders. AXS-12 (reboxetine) is a selective norepinephrine reuptake inhibitor and cortical dopamine modulator under investigation for the treatment of narcolepsy. In the Phase 3 SYMPHONY trial, AXS-12 met the primary endpoint, a statistically significant reduction in weekly cataplexy attacks from baseline to Week 5 versus placebo. Here, we report secondary endpoints assessing symptom severity, daily functioning, and mood. Methods SYMPHONY was a randomized, double-blind, placebo-controlled trial in patients with narcolepsy type 1 (NT1). Participants (15-75 years) were randomized 1:1 to AXS-12 or placebo for 5 weeks. Stable, concurrent modafinil/armodafinil use was allowed. Secondary endpoints included: the Clinical Global Impression of Severity (CGI-S) for narcolepsy, the Functional Outcomes of Sleep Questionnaire short version (FOSQ-10), and the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire anxiety/depression domain. Results Ninety participants were enrolled. At baseline, mean (SD) CGI-S for narcolepsy score was 5.2 (1.0) in the AXS-12 arm and 4.9 (1.0) in the placebo arm. AXS-12 led to a significant reduction versus placebo in CGI-S for narcolepsy at Week 5 (LS mean difference [95% CI]=0.72 [0.29, 1.16]; p=0.001). At baseline, mean FOSQ-10 total score was 11.1 (3.1) in the AXS-12 arm and 11.6 (3.2) in the placebo arm. AXS-12 led to a statistically significant improvement from baseline to Week 5 in FOSQ-10 total scores compared to placebo (1.66 [0.51, 2.82], p=0.005). At baseline, 47.8% of participants in the AXS-12 arm and 45.5% in the placebo arm reported anxiety/depression (EQ-5D-5L). A numerically greater proportion of participants achieved improvements on this domain with AXS-12 (55.0%) versus placebo (31.6%) at Week 5 (p=0.146). Conclusion AXS-12 demonstrated significant reductions in clinical impressions of narcolepsy symptom severity. Functional impairment due to EDS was also significantly reduced, in-line with previously reported improvement in clinician-rated assessments. Anxiety and depression-related symptoms showed trends favoring AXS-12. Combined with prior findings on cataplexy and cognitive improvements, these results highlight the potential of AXS-12 as a therapeutic option addressing multiple symptoms of narcolepsy which affect QoL and functioning. Support (if any) Axsome Therapeutics, Inc.